



SiloPharma

NOVEL THERAPEUTICS FOR UNMET MEDICAL NEEDS

**Investor Presentation
March 2026**

FORWARD-LOOKING STATEMENTS

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this document or to reflect the occurrence of unanticipated events except as required by law.

Novel Therapeutics for **UNMET MEDICAL NEEDS**

We are a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions.

- Post-traumatic stress disorder (PTSD)
- Stress-induced psychiatric disorders
- Fibromyalgia and chronic pain disorders
- Central nervous system (CNS) diseases

Our focus is on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems.

Multiple Levers for **VALUE CREATION**

- **Clear timeline to first-in-human clinical trials** for lead asset SPC-15 pending FDA guidance on pre-IND.
- **Exclusive global licenses** granted by Columbia University for two portfolio assets.
- **Streamlined 505(b)(2) regulatory pathway** for drug approval planned for priority drug candidates.
- **Diversified pipeline** of novel technologies and assets.
- **Market potential** in central nervous system therapeutics industry.
- **Assets well-protected** by strong intellectual property portfolio.
- **Sufficient capital resources** to support upcoming catalysts.
- **Accomplished leadership** with broad expertise in life sciences.

Under-Addressed **MEDICAL NEEDS**

Mental Health

SPC-15 | Intranasal PTSD treatment

- Selective intranasal drug compound (non-psychedelic)
- Patented nose-to-brain delivery bypasses blood-brain barrier
- Direct, heightened drug concentration in the brain
- Optimized patient safety and therapeutic delivery

Neurology

SPC-14 | Alzheimer's Disease

- Potential to improve and restore cognitive and memory function

Chronic Pain

SP-26 | Non-opioid pain solution

- Ketamine-based therapeutic implant targeting fibromyalgia
- Self-administered treatment
- Safely regulated dosage and time release


Silo Pharma's

DRUG PIPELINE

Our current assets have shown promise in a range of diseases and conditions including PTSD, chronic pain, Alzheimer's Disease, and multiple sclerosis.



Blood Brain Barrier



Route of nose to brain delivery

SPC-15:

PROPHYLACTIC TREATMENT FOR PTSD

Drug:

- Novel serotonin 4 (5-HT₄) receptor agonist that utilizes biomarkers for treatment

Stage:

- Pre-IND submitted for first-in-human trials

Unmet need:

- No new drug approvals for PTSD in nearly 25 years¹
- Affects estimated 3.9% of world's population¹
- Cumulative prevalence in young people doubled from 2017 to 2022 to 7.5%¹

Competitive advantages:

- Patented, cutting-edge intranasal nose-to-brain drug dispersion
- Nose-to-brain method increases drug's concentration in the brain
- Faster onset of therapeutic benefit and optimized safety

¹ FT Specialist, Endpoints in Focus, Lykos' pain is others' gain as psychedelic biotechs take notes from adcomm vote. June 2024.



SP-26:

KETAMINE IMPLANT FOR FIBROMYALGIA

Drug:

- Subcutaneous time-released ketamine-based injectable dissolvable implant

Stage:

- Preclinical research

Unmet need:

- Only FDA-approved drugs for fibromyalgia are 2 antidepressants and 1 anti-seizure medicine¹
- Chronic pain treatment market projected growth to \$106.3B in 2028 at 7.9% CAGR²
- Global fibromyalgia treatment market projected growth to \$4.1B in 2032 at 4.3% CAGR³

Competitive advantages:

- Innovative non-opioid chronic pain therapeutic
- Implant method designed to safely regulate dosage and time release
- Attractive alternative to intravenous delivery

¹ WebMD, *Fibromyalgia: Treatment and Medications*. February 2024.

² Business Research Company, *Chronic Pain Market Growth Analysis With Investment Opportunities For 2024-2033*. July 2024.

³ Precedence Research, *Fibromyalgia Treatment Market Size to Worth USD 4.13 Billion by 2032*. June 2024.

NEUROLOGY

SPC-14: ALZHEIMER'S DISEASE

Drug:

- Novel drug targeting two receptor molecules

Stage:

- Preclinical research

Unmet need:




- Treatment market projected growth to \$30.8B in 2033, at 18.8% CAGR¹

Competitive advantages:

- Has shown efficacy against luteinizing hormone (LH) in attenuating learned helplessness, preservative behavior, and hyponeophagia (a measure of anxiety)

¹ Market.us, Alzheimer's Disease Therapeutics Market Value to Reach USD 30.8 Billion by 2033 | Driven by the Advancements in Neurological Research. January 2024.

PIPELINE

Drug	Indication	Optimization/ Proof of Concept	Preclinical	Phase I	Phase II	Phase III	Launch	Next Milestone	
SPU-15 Mental Health	Stress-Induced Affective Disorder								FDA Type C Meeting Expected 2026
SP-26 Chronic Pain	Fibromyalgia								Evaluating 2026
SPC-14 Neurology	Alzheimer's Disease (AD)								Evaluating 2026

Creating
VALUE

Our strategic business platform supports our ongoing development of novel drugs with the potential to transform patient care.



FDA's 505(b)(2)

ABBREVIATED REGULATORY PATHWAY

Silo Pharma intends to utilize the FDA's streamlined 505(b)(2) pathway for its top two priority drug candidates, SPC-15 and SP-26.



Section 505(b)(2) of the Federal Food, Drug, and Cosmetics Act (FDCA)

- Streamlined pathway to New Drug Application (NDA) approval for novel repurposed drugs
- NDA relies upon publicly available data on active ingredient
- Can significantly shorten clinical timelines and reduce drug development costs

MANAGEMENT



Eric Weisblum **CEO**

- 20+ years investing, building and managing businesses
- Prior president of Sableridge Capital
- Former board member of Aikido Pharma, a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics



Daniel Ryweck **CFO**

- Certified Public Accountant
- Formerly chief compliance officer of Mill City Ventures III Ltd, interim chief financial officer of Sun BioPharma, Inc., and director of Dala Petroleum Corp.

KEY PERSONNEL



James Kuo, M.D., MBA **Vice President of R&D**

- Current managing director of Athena Bioventures
- Formerly held executive positions in private and listed bioscience companies in the U.S., Canada, and Europe
- Chairman of the Board of ImmunoPrecise Antibodies and board director of Tryp Therapeutics
- Former CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery¹³ Laboratories

BOARD OF DIRECTORS



Eric Weisblum **CEO**

- 20+ years investing, building and managing businesses
- Prior president of Sableridge Capital
- Former board member of Aikido Pharma, a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics



Wayne Linsley **Director**

- 40 years in business management
- Wide and varied skillset including sales and sales management, finance (public and private companies), accounting, audit support and financial reporting
- Independent director for Hoth Therapeutics Inc. (NASDAQ: HOTH) and DatChat Inc. (NASDAQ: DATS)



Kevin Muñoz M.D. **Director**

- Director of Operations at Physical Medicine and Rehabilitation
- Former researcher with Harlem Health Promotion Center in New York
- Doctor of Medicine from Xavier University School of Medicine, B.S. from University of Michigan with distinction



Jeff Pavell D.O. **Director**

- Site proctor for Rusk Institute residents training for Rehabilitation Medicine and Chief of Rehabilitation Medicine at Englewood Hospital and Medical Center in New Jersey
- Residency and chief residency at New York University Medical Center's Rusk Institute of Rehabilitation and Bellevue Hospital, respectively, New York College of Osteopathic Medicine with honors

Key Collaborations and INTELLECTUAL PROPERTY

Exclusive collaborations with prominent medical research partners provide valuable IP, assets, and time-to-market advantages.

Columbia University

- Exclusive worldwide rights to develop, manufacture, and commercialize SPC-15 and SPC-14
- Extensive issued and pending IP patent applications acquired with license agreement



University of Maryland, Baltimore

- Exclusive, worldwide, sublicensable, royalty-bearing Master License Agreement for SPU-16
- Rights to central nervous system-homing peptides for investigation and treatment of multiple sclerosis and other neuroinflammatory pathology

CRO & Manufacturing Partners include...



Creating **VALUE**

SPC-15

Pathway to
first-in-human
trials

Market Size

Large CNS
markets

SP-26

Non-opioid
pain relief

Partners

Prominent
collaborations

502(b)(2)

Streamlined pathway
to FDA approval

Credentials

Broad life sciences
expertise

Exclusivity

Strong asset
protection

Capital

Sufficient
resources, no debt



Thank you.

Silo Pharma, Inc. | 677 N. Washington Blvd., Sarasota, FL 34236
Investor Relations Contact: 800-705-0120 | investors@silopharma.com